ÉúÎïѧ½¹Óò,biological focal regionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ïà¶ÔÉúÎïѧЧӦ,Relative biological effectivenessÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
³¬ÉùÈÈÁÆ,ultrasound hyperthermiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
PPS³éÑù,PPS samplingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
CdSÁ¿×Óµã,CdS quantum dotsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÔöÖ³ÓëµòÍö,Proliferation and apoptosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°¢¿ËÀÃ¹ËØA,Aclacinomycin AÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÔʼÉñ¾ÍâÅßÒ¶Áö,primitive neuroectodermal tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÇСϸ°û,non-small cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½ÚÂÉ»¯ÁÆ,Metronomic chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÄÍÒ©,Drug resistanceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÇÕÛµþµ°°×·´Ó¦,unfolded protein responseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°û¹ý¼ÌÃâÒßÖÎÁÆ,Adoptive cellular immunotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×ªÒÆÁܰͽá,metastatic lymph nodesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×éÖ¯¿éÅàÑø,explant cultureÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»îÔØÌåÒßÃç,live vector vaccineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾Æ¤ÉöÔìðüÊõ,Percutaneous nephrostomyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐÅÏ¢´«µ¼,Signal transductionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µ°°×¹¹Ïó,protein conformationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°ûÉú³¤ÇúÏß,Cell growth curveÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´ÅÐÔÄÉÃײÄÁÏ,magnetic nanomaterialsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈȲÎÊý,thermal parameterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
΢ÐÍÓлúºÏ³É,microscale organic synthesisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Õæ¿Õ´ü,vacuum bagÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¦Ã-°±»ù¶¡ËáÊÜÌå,GABA receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸Îϸ°ûÐԸΰ©,Hepatocellular carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°©Ö¢·ÖÀà,cancer classificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ñÐÔÏËά×é֯ϸ°ûÁö,Malignant fibrous histiocytomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ì岿Ö×Áö,body tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Î°©Ò׸ÐÐÔ,lung cancer susceptibilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
±ÊÐÎÊø,pencil beamÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
È˶ËÁ£Ã¸Äæ×ªÂ¼Ã¸Æô¶¯×Ó,hTERT promoterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÇÖÏ®ÐÔÏËάÁö²¡,Aggressive fibromatosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
É䯵ÈÈÁÆ,Radiofrequency hyperthermiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½ºÔ¢ôÐÍ,collagen type ¢ôÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉúÎï¼î²¿Î»,alkaloid fractionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ñÐÔ¸¹Ç»»ýÒº,malignant ascitesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
TP·½°¸,TP regimenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×éµ°°×¼×»ù×ªÒÆÃ¸,histone methyltransferaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶àÒ¶¹âÕ¤,multileaf collimatorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈÈÏûÈÚ,Thermal ablationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
L-929ϸ°û,L-929 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÔàÆ÷¹¦ÄÜ,Organ functionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ô°©»ùÒòµ°°×ÖÊc-mdm2,Proto-oncogene proteins c-mdm2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖØÀë×ÓÖΰ©,heavy-ion cancer therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖܼÁÁ¿,weekly doseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÈܽâ×ÛºÏÕ÷,Tumor lysis syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈÍ´øÑùÐÍÏËάÁö²¡,desmoid-type fibromatosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
С¼ÁÁ¿»¯ÁÆ,Low dose chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾Ö²¿¶¾ÐÔ,local toxicityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ÇËèÎ¢×ªÒÆ,Bone marrow micrometastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µ¥´¿ðåÕ¶¾ÐØÜÕ¼¤Ã¸»ùÒò,Herpes simplex virus thymidine kinase geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ȾɫÌå²»Îȶ¨,chromosomal instabilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µ°°×Á×Ëáø2C,Protein phosphatase 2CÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°©ÒßÃç,cancer vaccineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½Ç¶ÈÓÅ»¯,angle optimizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒìÁòÇèËáÜÐõ¥,benzyl isothiocyanateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉúÎï¶àÌÇ,biological polysaccharideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÂÈ»¯¸ÆÈÜÒº,CaCl_2 solutionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ü°²Ã¸ÁªÃâÒß·ÖÎö,voltammetric enzyme-linked immunoassayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼ÓζС²ñºúÌÀ,Modified Minor Radix Bupleuri DecoctionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÇÖÏ®ÐÔÏËάÁö,aggressive fibromatosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
N-ras»ùÒò,N-ras oncogeneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´ÙÏËάÔöÉúÐÔСԲϸ°ûÖ×Áö,desmoplastic small round cell tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
EC9706,EC9706 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ò½ÓûúÆ÷ÈË,Medical RobotÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖÎÁƼƻ®ÏµÍ³,treatment planning systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°ÐÇø¹´»,Target delineationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÂËÅÝÊ÷ͻ״ϸ°û,follicular dendritic cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈýάÊÊÐÎ,Three-dimensional conformalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ÐÓ¦¼ÓÎÂ,Inductive heatingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÖÎÓú,tomor rejectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
±í¹ÛÒÅ´«Ñ§µ÷¿Ø,epigenetic regulationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
EphÊÜÌå,Eph receptorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾«È··ÅÁÆ,precise radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áöɸ²é,tumor screeningÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ÇÖ×Áö/¼Ì·¢ÐÔ,Bone Neoplasms/secondaryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Rb94»ùÒò,Rb94 GeneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÒÖÖÆÒò×Ó,Tumor suppressorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ß¼ÁÁ¿ÂÊ,High dose rateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈËÈéÍ·×´Áö²¡¶¾16ÐÍ,Human papillomavirus type 16Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ïû¼«°²ÀÖËÀ,passive euthanasiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ñÐÔ/Ò©ÎïÁÆ·¨,malignant/drug therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÌÛÍ´»º½â,Pain reliefÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ѪÇå·´Ó¦Òò×Ó,Serum response factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¦Á-ÉúÓý·ÓçúçêËáõ¥,¦Á-Tocopheryl succinateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µç×ÓÉäÒ°Ó°Ïñϵͳ,Electronic portal imaging deviceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éñ¾ÏµÍ³¸±Ö×Áö×ÛºÏÕ÷,paraneoplastic syndrome of nervous systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ʹÓ÷ÖÎö,analysis of useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
von Hippel-Lindau×ÛºÏÕ÷,von Hippel-Lindau syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÜЧÒò×Ó,Energy efficiency factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹Ç×ªÒÆÌÛÍ´,metastatic bone painÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
GAGE»ùÒò,GAGE GeneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÍâÖÜѪDNA,peripheral blood DNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áö½þÈóÊ÷ͻ״ϸ°û,tumor infiltrating dendritic cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÇàÝïËØÑÜÉúÎï,artemisinin derivativesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶àÐÎÐÔ½ºÖÊĸϸ°ûÁö,Glioblastoma multiformeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÅÁÃ×Á×Ëá¶þÄÆ,Pamidronate disodiumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐØÇ»ÄÚ»¯ÁÆ,intrapleural chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Èý½×ÌÝֹʹ,three-step analgesic ladderÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«

|